Burger - Figure 26
Squamous Cell Cancer Data (Continued)
FIG. 26: In the study introduced in Figure 25,[16] outcomes with trimodal therapy were comparable in pure urothelial carcinoma and variant cases, of which 76% were squamous variant. The 10-year overall survival was around 40% in both groups (Figure, left), and bladder-intact disease-specific survival rates were also similar (Figure, right). Although outcomes appear similar in both groups, the 10-year cystectomy rate is decisively higher for variant cases, being 28% vs 19% for pure urothelial carcinoma. These rates are fairly high, but are more pronounced for variant histology.
References
Krasnow RE, Drumm M, Roberts HJ, et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol. 2017;72:54−60 http://dx.doi.org/10.1016/j.eururo.2016.12.002
